PAT-1251 is primarily investigated for its potential therapeutic applications in the field of oncology. It is being studied as a targeted therapy for certain types of cancer, particularly those driven by specific genetic mutations or pathways. Researchers are exploring its efficacy in inhibiting key molecular targets that play a role in tumor growth and progression. Early-stage clinical trials are focused on evaluating its safety, tolerability, and effectiveness in patients with advanced or refractory cancers. If successful, it could offer a new treatment option for patients with limited therapeutic alternatives. Additionally, its mechanism of action is being analyzed to understand its potential in combination therapies with other anticancer agents.